EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatments are recommended for NSCLC patients with two most common sensitizing mutations (exon 19 E746-A750 deletion and exon 21 L858R) [11].